Join us in London in March 2019 for our 3rd annual Drug Discovery Chemistry conference

1. www.drug-discovery.co.uk
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
CHAIRS FOR 2019:
• Roderick Hubbard, Professor, University of York, and Senior
Fellow, Vernalis Research Ltd
• Darren Green, Director of Molecular Design, GSK
KEY SPEAKERS INCLUDE:
• Roland Bürli, Senior Director, Head of Medicinal Chemistry
Neuroscience, AstraZeneca
• Tobias Gabriel, Global Head of Discovery Chemistry,
Novartis
• Govinda Bhisetti, Principal Investigator and Head of
Computational Chemistry, Biogen
• Hasane Ratni, Expert Scientist, F Hoffmann-La Roche
• Alexander Hillisch, Director of Medicinal Chemistry, Bayer
• Andrew Popplewell, Head of Antibody Discovery and
Engineering, UCB
• Phil Cox, Senior Principal Research Scientist, AbbVie
HIGHLIGHTS IN 2019:
• Discuss the impact of the use of novel computational
techniques on R&D pipelines
• Hear about the progress in the development of
new drugs on difficult targets and how these can
revolutionise patient treatment
• Discover how AI is being utilised in the commercial
setting and opportunities to best exploit these to
streamline the drug discovery process
• Explore the potential of new modalities to transform
therapeutics
• Learn about current strategies to increase drug
discovery success
CONFERENCE: 18TH - 19TH
WORKSHOP: 20TH
MAR
2019COPTHORNE TARA HOTEL, LONDON, UK
Developing your R&D pipeline with strategies to
deliver small molecules
SMi presents their 3rd Annual Conference on…
Drug Discovery
Chemistry
BOOK BY 30 NOVEMBER AND SAVE £400
BOOK BY 14 DECEMBER AND SAVE £200
BOOK BY 31 JANUARY AND SAVE £100
SMi Pharma
@SMiPharm
#SMiDrugDisChem
Artificial Intelligence in Drug Discovery
Workshop Leader:
Dr Nick Camp, Drug Discovery Consultant, Nick Camp Consulting Ltd
8.30am-12.30pm
PLUS AN INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOP | WEDNESDAY 20TH MARCH 2019, COPTHORNE TARA HOTEL, LONDON, UK

2. Drug Discovery Chemistry
Day One | Monday 18th March 2019 www.drug-discovery.co.uk
8.30 Registration & Coffee
9.00 Chair’s Opening Remarks
Roderick Hubbard, Professor, University of York, and Senior Fellow,
Vernalis Research Ltd
NEW MODALITIES IN DRUG DISCOVERY CHEMISTRY
OPENING ADDRESS
9.10 Winning for the future: strategies to deliver small molecules
• Utilising strategic medicinal chemistry techniques to optimise
the small molecule drug discovery process
• Implementation of faster screening and target validation
techniques and its implications on the drug discovery process
• Streamlining of the R&D process with medicinal chemistry
techniques
Tobias Gabriel, Head, External Science & Drug Discovery,
Novartis Institutes for BioMedical Research, Inc.
9.50 Protein degradation in drug discovery - PROTACs and its
uses within the field
• The emerging technique of utilising PROTACs to target proteins
and its advantages in target validation
• The prospects of using PROTACs in therapeutics
• The limitations of PROTACs and how to utilise them in the clinic
• IMiDs and molecular glues
Markus Queisser, Scientific Leader, GlaxoSmithKline
10.30 Morning Coffee
11.00 Enabling drug discovery for challenging targets — Mcl-1 and Bcl-2
• Enabling drug discovery against challenging targets
• The importance of biophysical methods in target evaluation
and characterisation
• From fragment hits to clinical candidates
Roderick Hubbard, Professor, University of York, and Senior Fellow,
Vernalis Research Ltd
11.40 Antibodies and their potential within drug discovery
• Novel modalities of antibodies in drug discovery: antibody drug
conjugates and novel scaffolds of Fc-regions with enhanced
effector activities
• Technological advances in antibody discovery, expression,
engineering and its contribution to antibody candidate
molecules
• Drug conjugates and aspects of their design and delivery –
linker strategies, bystander effects etc.
• The future of antibodies in therapeutics.
Andrew Popplewell, Head of Antibody Discovery and Engineering,
UCB
12.20 Networking Lunch
1.20 Discovery of Risdiplam, a selective survival of Motor Neuron-2
(SMN2) gene splicing modifier for the treatment of Spinal Muscular
Atrophy (SMA)
• Concept of gene splicing modulation
• Medicinal chemistry optimization leading to the discovery of
risdiplam
• Selectivity (vs other genes) as a key aspect
• Safety characterisation
Hasane Ratni, Expert Scientist, F Hoffmann-La Roche
DRUG DISCOVERY OPTIMISATION TECHNIQUES
2.00 Macrocycles - their uses, advantages and synthesis for
commercial use
• Macrocycles as an emerging part of chemical space and it’s
potential to drug difficult genomic targets
• How the synthesis of Macrocycles using the Multicomponent
Reaction Chemistry (MCR) can provide molecular diversity and
complexity at low synthetic costs
• Current technologies implemented at Cyclenium
• The future in circumventing major permeability and
bioavailability obstacles in macrocycle use
Helmut Thomas, President and CEO, Cylenium Pharma
2.40 DNA encoded libraries and their practical uses
• Discuss the design of DNA encoded libraries at NIBR
• Insight into Novartis’ schemes for innovation in DEL
• Case study
Frederic Berst, Senior Investigator, Novartis
3.20 Afternoon Tea
3.50 Important aspects of fragment based library design- Ro3 and
Beyond
• Ro3 covers the idealized physicochemical property space of
fragments but what other factors are important for fragment
design?
• What is the sweet spot for saturation (Fsp3) of fragments?
• Shape-based considerations- flat, 3D, or somewhere in
between?
• Fragment follow-up: encoding chemistries into fragment libraries
• Case study of how our newly designed fragments enabled a
fragment to lead campaign in short order
Phil Cox, Senior Principal Research Scientist, AbbVie
4.30 NMR fragment screening in early stage drug discovery
• Introduction to NMR screening methods – both ligand and
protein observe
• Practical considerations of NMR fragment screening
• Confirmation and elaboration of NMR fragment hits
• Case study: Combining NMR fragment screening and
orthogonal screening techniques
Christine Prosser, Principal Scientist, UCB
5.10 Chairman’s Closing Remarks and Close of Day One
Register online at www.drug-discovery.co.uk
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime
networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your
industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
OFFICIAL MEDIA PARTNERS:

3. Drug Discovery Chemistry
www.drug-discovery.co.uk Day Two | Tuesday 19th March 2019
8.30 Registration & Coffee
9.00 Chair’s Opening Remarks
Darren Green, Director of Molecular Design, GlaxoSmithKline
TARGET EXPLORATION IN DRUG DISCOVERY
OPENING ADDRESS
9.10 Chemical biology - new approaches to drug the undruggable
• New technologies
• New modalities
• Where to play and how to win
Ulrich Schopfer, Head of Integrated Target & Lead Discovery,
Novartis
9.50 Computational chemogenomics and utilisation of AI
• The future of computational chemogenomics – the genome
wide search for druggable interactions
• Efficient utilisation of AI within the computational
chemogenomic space
• Highlights from recent case studies
Edgar Jacoby, Senior Principal Scientist Computational Chemistry,
Janssen
10.30 Morning Coffee
11.00 Arsenic Methyl Transferase and its potential role in CNS
• Discovery of a form of arsenic methyl transferase (AS3MT)
as a potential risk factor for schizophrenia
• Molecular modelling, virtual screen, hit identification
• The biological role of AS3MT – identification of potential
interaction partners
Roland Burli, Senior Director, Head of Medicinal Chemistry,
Astrazeneca
ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING
11.40 Using Artificial intelligence in early drug discovery
• Advances in how artificial intelligence can be used to identify
druggable targets
• The ability of AI to prioritise drug targets and it’s uses in
preventing drug discovery failures
• The opportunities of deep learning in the drug discovery process
Vivek Vishnudas, Sr Vice President Drug Discovery & Platform
Sciences, Berg LLC
12.20 Networking Lunch
1.20 Next generation drug discovery: Encoded Library Technology in
Nanospheres
• Nanna Therapeutic’s proprietary screening and AI platform
(T.I.M.E.) to speed-up drug discovery
• Encoded Library Technology in Nanospheres: Expanding the
boundaries of bio-relevant chemical space
• Highlights from recent case studies
James Dale, Senior Scientist and Head of Chemistry,
Nanna Therapeutics
2.00 Utilising AI in structure based drug design and the
implications of virtual screening
• Overview of the quantum computing molecule
comparison and its implications in speeding the DD process
• The role of computational techniques in streamlining the
structure-based drug design process
• The utilisation of machine learning models in ADME optimisation
in drug design and development
• The applications of virtual screening and molecular
comparative tools in development of drugs for
neurodegenerative disorders – case study
Govinda Bhisetti, Principal Investigator and Head of
Computational Chemistry, Biogen
2.40 When the rubber hits the road: The application of AI across
drug discovery
The talk will focus on the application of AI to:
• Target Identification
• Medicinal Chemistry
• Patient Stratification
Chris Tame, Research Leader, BenevolentAI
3.20 Afternoon Tea
3.50 Next-Generation drug discovery: quantum physics meets machine
learning
• Traditional approaches to in-silico drug discovery have been
hampered by incomplete and inaccurate representation of
molecules
• This leads to poorly performing predictive models of efficacy
and safety and inability to fully probe all the drug-like chemical
space
• GTN’s unique and proprietary platform combines deeper
featurization of molecules using quantum mechanical
descriptors with cutting-edge generative machine learning
models to quickly generate novel intellectual property at scale
• This presentation gives an overview of the GTN platform,
highlights an industrial case study and identifies future
opportunities for the approach
Graham Simpson, Head of Drug Discovery, GTN
4.30 Machine Learning for Drug Discovery
• The use of Machine Learning for ADME prediction
• The utilisation of these outcomes in determining next steps in the
drug discovery process
• Case studies
Alexander Hillisch, Director, Medicinal Chemistry, Bayer
5.10 Chairman’s Closing Remarks and Close of Day Two
Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
SUPPORTED BY:
MARKETING PARTNERSHIP OPPORTUNITIES
SMi Group is offering companies the opportunity to partner on our dedicated events in order to help raise your company profi le,add value,
create awareness of your products/services to our key audience within the pharmaceutical industry. Interested in partnering?
Contact Simi Sapal, Marketing Manager on +44 (0) 20 7827 6000 or email: ssapal@smi-online.co.uk

4. HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 20th March 2019
Copthorne Tara Hotel, London, UK
8.30am - 12.30pm
Artificial Intelligence in
Drug Discovery
Workshop Leader:
Dr Nick Camp, Drug Discovery Consultant,
Nick Camp Consulting Ltd
Workshop overview:
The workshop will evaluate the current status of Artificial
Intelligence within the drug discovery industry. The sessions
will focus upon current opportunities, challenges and future
direction for this technology.
Why you should attend this workshop:
• Identify opportunities for application of AI within drug
discovery
• Learn about the current landscape for AI based
companies
• Understand the challenges associated with the
adoption of AI
• Input ideas towards a fully integrated drug discovery
platform
• Networking and collaboration
Agenda
8.30 Registration and Coffee
9.00 Introduction
9.10 Session 1: Opportunities for Artificial Intelligence
(AI) within drug discovery
• At what stages of the drug discovery cycle can
AI be applied?
• Where can AI have the greatest impact?
9.45 Session 2: Applying AI within the drug discovery
industry
• What are the challenges? How can we
overcome them?
• What are your experiences working with AI
based companies?
10.20 Coffee
10.45 Session 3: Current status: What is available and
what is missing?
• Many AI companies exist. How do you find the
right partner?
• Does the current landscape of AI companies
cover all the stages of drug discovery?
11.20 Session 4: How to utilise AI in a fully integrated
drug discovery platform
• Would it be an advantage or more attractive
to have all AI technology under a single drug
discovery platform? What would your platform
contain?
• How much can be done in silico (screening,
hit identification etc) prior to committing to
laboratory work?
12.00 Discussion
12.30 Closing Remarks
About the Workshop Leader:
Dr Nick Camp runs an independent and international Drug
Discovery Consultancy Company. Works with Pharma,
CROs, Biotech, Start-Ups, Charities and Academia across
Europe, US and Asia. Specialising in Medicinal Chemistry,
Drug Discovery Partnerships, Business Development and
Disruptive Technologies. Helps Clients to identify Business
Partners through extensive network and provides technical
support. Available for one-off, short and long-term Drug
Discovery and Medicinal Chemistry Consultancy. Please
see website www.ncampconsulting.com for more

5. SMi PHARMACEUTICAL
EVENT PLANNER 2019
JANUARY 2019
Pre-Filled Syringes & Injectable Drug Devices
16th -17th January, London, UK
Pharmaceutical Microbiology
21th - 22th January, London, UK
Social Media in the Pharmaceutical Industry
21st - 22nd January, London, UK
FEBRUARY 2019
Parallel Trade
5th - 6th February, London, UK
3D Cell Culture
20th - 21st February, London, UK
RNA Therapeutics
20th - 21st February, London, UK
MARCH 2019
Superbugs & Superdrugs
18th - 19th March 2019, London, UK
Drug Discovery Chemistry
18th - 19th March 2019, London, UK
APRIL 2019
Adaptive Designs
1st - 2nd April 2019, London, UK
Pre-Filled Syringes East Coast
8th - 9th April 2019, Boston, USA
Microbiology East Coast
10th - 11th April 2019, Boston, USA
MAY 2019
Highly Potent Active Pharmaceutical Ingredients
13th - 14th May 2019, London, UK
Pain Therapeutics
13th - 14th May 2019, London, UK
Injectable Drug Delivery
15th - 16th May 2019, London, UK
JUNE 2019
Prefilled Syringes West Coast
3rd - 4th June 2019, San Diego, USA
Lyophilisation
3rd - 4th June 2019, London, UK
Microbiology West Coast
5th - 6th June 2019, San Diego, USA
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising
and branding packages, uniquely tailored
to complement your company’s marketing
strategy. Prime networking opportunities exist to
entertain, enhance and expand your client base
within the context of an independent discussion
specific to your industry. Should you wish to join
the increasing number of companies benefiting
from sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or email:
amalick@smi-online.co.uk

6. DRUG DISCOVERY CHEMISTRY 2019
Conference: 18th - 19th March 2019, Copthorne Tara Hotel, London, UK Workshop: 20th March 2019, Copthorne Tara Hotel, London, UK
4 WAYS TO REGISTER
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
ONLINE at www.drug-discovery.co.uk
POST your booking form to: Events Team, SMi Group Ltd,
1 Westminster Bridge Road, London, SE1 7XW
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk
Unique Reference Number
Our Reference P-279
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-279 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
SMi Group will apply surcharges to commercial cards
Please tick here □ if the card provided is not a commercial card
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
DOCUMENTATION
I cannot attend but would like to Purchase access to the following Document Portal/
Paper Copy documentation. Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
PAYMENT
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged
on Document portal and literature distribution for all UK customers and for those EU
Customers not supplying a registration number for their own country here
CONFERENCE PRICES GROUP DISCOUNTS AVAILABLE
I would like to attend: (Please tick as appropriate) Fee TOTAL
□ Conference Workshop £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
□ Workshop only £599.00 + VAT £718.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to
the Document Portal. Presentations that are available for download will be subject
to distribution rights by speakers. Please note that some presentations may not be
available for download. Access information for the document portal will be sent to
the e-mail address provided during registration. Details are sent within 24 hours post
conference.
□ Book by 30th November to receive £400 off the conference price
□ Book by 14th December to receive £200 off the conference price
□ Book by 31st January to receive £100 off the conference price
EARLY BIRD
DISCOUNT
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
If you would like to continue to receive email updates about our
events, please tick □
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send
a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the
event. Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifically to order. If we
have to cancel the event for any reason, then we will make a full refund immediately, but disclaim
any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Privacy policy / Opt Out: For full details on our privacy policy please go to
http://smi-online.co.uk/privacy-legals/privacy-policy. If you no longer wish to receive email
updates you can opt out by going to the following webpage http://www.smi-online.co.uk/opt-out
Terms and Conditions of Booking
DELEGATE DETAILS
VENUE Copthorne Tara Hotel, London, UK
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712